Melanosomal targeting sequences from gp100 are essential for MHC class II-restricted endogenous epitope presentation and mobilization to endosomal compartments.
CD4+ T lymphocytes play an important role in CD8+ T cell-mediated responses against tumors. Considering that approximately 20% of melanomas express MHC class II, it is plausible that concomitant presentation by MHC class I and class II shapes positive (helper T cells) or negative (regulatory T cells) antitumor responses. Interestingly, gp100, a melanoma antigen, can be presented by both MHC class I and class II when expressed endogenously, suggesting that it can reach endosomal/MHC class II compartments (MIIC). Here, we showed that gp100 putative NH2-terminal signal sequence and the last 70 residues in COOH terminus are essential for MIIC localization and MHC class II presentation. Confocal microscopy analyses confirmed that gp100 was localized in LAMP-1+/HLA-DR+ endosomal/MIIC. Gp100 targeting sequences were characterized by deleting different sections in the COOH terminus (last 70 residues). Transfection in 293T cells, expressing MHC class I and class II molecules, revealed that specific deletions in COOH terminus resulted in decreased MHC class II presentation, without effects on class I presentation, suggesting a role in MIIC trafficking for these deleted sections. Then, we used these gp100 targeting sequences to mobilize green fluorescent protein to endosomal compartments and to allow MHC class II and class I presentation of minimal endogenous epitopes. We conclude that these specific sequences are MIIC-targeting motifs, which could be included in expression cassettes for endogenously expressed tumor or viral antigens for MHC class II and class I presentation and optimize in vivo T-cell responses or as an in vitro tool for characterization of new MHC class II epitopes.
Research Centre, Centre Hospitalier de l'Université de Montréal, Hôpital Notre Dame, Université de Montréal and Institut du Cancer de Montréal, Montréal, Québec, Canada.
Stéphanie
S
Lepage
Réjean
R
Lapointe
D017951:Antigen Presentation / Q000276:immunology*; D019013:CD40 Antigens / Q000276:immunology; D011992:Endosomes / Q000276:immunology / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D049452:Green Fluorescent Proteins / Q000378:metabolism; D015234:HLA-A Antigens / Q000235:genetics / Q000276:immunology; D015789:HLA-A2 Antigen; D006684:HLA-DR Antigens / Q000235:genetics / Q000276:immunology*; D006801:Humans; D051907:Lysosomal Membrane Proteins / Q000276:immunology; D020460:Melanosomes / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D008562:Membrane Glycoproteins / Q000276:immunology* / Q000494:pharmacology; D009363:Neoplasm Proteins / Q000276:immunology* / Q000494:pharmacology; D013601:T-Lymphocytes / Q000276:immunology; D014162:Transfection; D058951:gp100 Melanoma Antigen; D052118:Lysosomal-Associated Membrane Protein 1
D019013:CD40 Antigens; D000939:Epitopes; D049452:Green Fluorescent Proteins; D015234:HLA-A Antigens; D015789:HLA-A2 Antigen; D006684:HLA-DR Antigens; D051907:Lysosomal Membrane Proteins; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D058951:gp100 Melanoma Antigen; C435939:HLA-A*02:01 antigen; C489116:LAMP1 protein, human; D052118:Lysosomal-Associated Membrane Protein 1; C548637:PMEL protein, human